4547:TYO
Kissei Pharmaceutical Co Ltd
3 830,00 JP¥
0,00%
(0,00) 1K
1-okt, 15:30:00 (GMT+9) · JPY
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_auto4547 tikeri uchun statistika yaratilmoqda...
Bozor kapitali
178,26 mlrd
Oʻrtacha hajm
66,55 ming
Hajmi
0,00
Dividend
3,13%
Choraklik dividendlar
30 JP¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
11,35
52 haftalik eng yuqori
5 040 JP¥
52 haftalik eng past
3 500 JP¥
Aksiya boʻyicha daromad
337 JP¥
Muomaladagi aksiyalar
46,72 mln
Xodimlar soni
2 ming
Bozor kapitali
178,26 mlrd
Oʻrtacha hajm
66,55 ming
Hajmi
0,00
Dividend
3,13%
Choraklik dividendlar
30 JP¥
Eks-dividend sanasi
29-sen, 2026
P/E koeffitsiyenti
11,35
52 haftalik eng yuqori
5 040 JP¥
52 haftalik eng past
3 500 JP¥
Aksiya boʻyicha daromad
337 JP¥
Muomaladagi aksiyalar
46,72 mln
Xodimlar soni
2 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Simply Wall Street
·
10 daqiqa oldin
EquipmentShare.com (EQPT) Commits To 1 Gigawatt Of Power Capacity
TradingView
·
41 daqiqa oldin
S&P 500, Nasdaq, Dow Futures Inch Higher As Investors Cheer Cooling Yields — GOOGL, MU, MAT, NVDA In Focus
MarketWatch
·
58 daqiqa oldin
Here’s who’s joining the S&P 500 in the index’s latest shakeup
Fox Business
·
2 soat oldin
October could be a huge month for the stock market. Here's why.
Profil
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
Kissei Pharmaceutical Co Ltd haqida
CEOMutsuo Kanzawa
Xodimlar soni1,79 ming
Asos solingan9-avg, 1946
Bosh ofislarMatsumoto, Nagano, Yaponiya
Sektor-
Veb-saytkissei.co.jp